Hypoxic antiblastic stop-flow perfusion: clinical outcome and pharmacokinetic findings.

Abstract

Stop-flow perfusion (SFP) is a recently implemented locoregional treatment based on the vascular isolation of the tumor bearing body district through a radiointerventistic technique. SFP is currently under investigation as a palliative therapeutic option for patients with locally advanced tumors. This paper reports on the results of our prospective study of limb and pelvic SFP. Thirty-seven patients were treated with SFP. No postoperative deaths occurred. Locoregional and systemic toxicity were observed after 22 and 31 treatments, respectively; complete and partial response after 3 (6%) and 24 (51%) SFPs, respectively. The pharmacokinetic study showed that pelvic SFP was associated with a leakage rate higher than femoral SFP (38% vs 28%). In conclusion, SFP is a feasible procedure. Toxicity and tumor response rates strictly depend upon drug leakage control.

• Authors: D Miotto, D Miotto, S Bertolo, M Minante, T Darisi, S Mocellin, D Casara, C Ori, M Foletto, C R Rossi, M Lise, D Nitti
• Journal: Journal of chemotherapy (Florence, Italy) (J Chemother) Vol. 16 Suppl 5 Pg. 44-7 (Nov 2004) ISSN: 1120-009X [Print] England
• PMID: 15675477 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Melphalan

Topics

• Adult
• Aged
• Antineoplastic Agents (administration & dosage, pharmacokinetics)
• Chemotherapy, Cancer, Regional Perfusion (methods)
• Female
• Humans
• Male
• Melphalan (pharmacokinetics)
• Middle Aged
• Neoplasms (drug therapy, mortality)
• Prospective Studies